Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 15MEQ K versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 15MEQ K versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K) vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides a source of calories and energy; sodium chloride and potassium chloride replenish electrolytes and maintain fluid balance.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion at a rate of 100-200 mL/hour (2-4 mL/kg/hour) based on fluid and electrolyte requirements. Maximum infusion rate: 1000 mL/hour. Adjust according to serum potassium levels.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Not applicable as terminal half-life for dextrose is not defined due to rapid metabolism; for potassium, distribution half-life ~1-1.5 h, terminal half-life ~12-24 h reflecting renal elimination.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: glucose is completely reabsorbed under normal conditions; excess is excreted unchanged in urine. Sodium, chloride, and potassium are primarily excreted renally, with >90% of infused loads eliminated by kidneys. Fecal and biliary excretion are negligible.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte